Can't get Baricitinib (Olumiant)? Explore real alternatives like Tofacitinib, Upadacitinib, and Ritlecitinib — including how they compare and what to ask your doctor.
If you've been prescribed Baricitinib (Olumiant) and can't fill your prescription — whether due to availability, insurance issues, or cost — you're probably wondering: what else can I take?
The answer depends on your specific condition, medical history, and what your doctor recommends. But there are several alternatives in the same drug class that may work for you. In this guide, we'll walk through what Baricitinib does, how it works, and the most common alternatives your doctor might consider.
Important: Never switch medications on your own. Always talk to your doctor before making any changes to your treatment plan.
Baricitinib is a Janus kinase (JAK) inhibitor sold under the brand name Olumiant. It's manufactured by Eli Lilly and Company and comes as a tablet you take once daily by mouth.
The FDA has approved Baricitinib for:
For a complete overview, visit our guide on what Baricitinib is and how it's used.
Baricitinib works by blocking two specific enzymes called JAK1 and JAK2. These enzymes are part of the JAK-STAT signaling pathway, which helps immune cells communicate and activate. When JAK1 and JAK2 are overactive, they can trigger too much inflammation — leading to joint damage in rheumatoid arthritis or hair follicle destruction in alopecia areata.
By inhibiting these enzymes, Baricitinib turns down the immune system's overreaction without shutting it off completely. Learn more in our detailed mechanism of action explainer.
If you can't get Baricitinib, the following medications work through similar mechanisms. Your doctor will help determine which one is right for your specific condition.
Drug class: JAK inhibitor (JAK1, JAK2, JAK3)
FDA-approved for: Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis
How it's taken: Oral tablet, 5 mg or 10 mg, taken twice daily (or 11 mg extended-release once daily)
How it compares: Tofacitinib is the most established JAK inhibitor, approved since 2012. It blocks JAK1, JAK2, and JAK3, making it slightly broader than Baricitinib. For rheumatoid arthritis patients, it's often a direct alternative. It is not FDA-approved for alopecia areata, though some doctors may use it off-label.
Cost: Around $2,400 to $2,800 per month without insurance. Generic Tofacitinib may become available, which could reduce costs significantly.
Drug class: Selective JAK1 inhibitor
FDA-approved for: Rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis
How it's taken: Oral tablet, 15 mg or 30 mg once daily
How it compares: Upadacitinib is a newer JAK inhibitor made by AbbVie that selectively targets JAK1. It has one of the broadest indication profiles of any JAK inhibitor. For rheumatoid arthritis, it's considered a strong alternative to Baricitinib. It is not currently approved for alopecia areata.
Cost: Approximately $2,700 to $3,200 per month without insurance. AbbVie offers savings programs for eligible patients.
Drug class: JAK3/TEC family kinase inhibitor
FDA-approved for: Severe alopecia areata in adults and adolescents aged 12 and older
How it's taken: Oral capsule, 50 mg once daily
How it compares: If you take Baricitinib specifically for alopecia areata, Ritlecitinib is the most direct alternative. It was approved by the FDA in 2023 and targets a different combination of kinases (JAK3 and TEC family). It does not carry the same boxed warning about cardiovascular events and malignancies that other JAK inhibitors have, though long-term safety data is still being collected.
Cost: Around $2,500 to $3,000 per month without insurance. Pfizer offers a savings program for eligible patients.
Drug class: Selective JAK1 inhibitor
FDA-approved for: Moderate-to-severe atopic dermatitis in adults
How it's taken: Oral tablet, 100 mg or 200 mg once daily
How it compares: Abrocitinib is primarily an option if Baricitinib is being used off-label for atopic dermatitis. Made by Pfizer, it selectively targets JAK1 and is specifically designed for skin inflammation. It would not be appropriate for rheumatoid arthritis or alopecia areata.
Cost: Approximately $2,600 to $3,100 per month without insurance.
The best alternative depends on:
Talk to your doctor about which alternative makes the most sense for you. You can also check availability and pricing for these medications on Medfinder.
Not being able to fill your Baricitinib prescription is frustrating, but you have options. Several JAK inhibitors are available that work through similar mechanisms and may be covered by your insurance. The key is working with your doctor to find the right fit.
Before switching, you might also want to try our tips for finding Baricitinib in stock or explore savings programs that could make the original prescription more accessible.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
